Abstract:Abstract Bone homeostasis and hematopoiesis are irrevocably linked in the hypoxic environment of the bone marrow. Erythropoietin (Epo) regulates erythropoiesis by binding to its receptor, Epor, on erythroid progenitor cells. The continuous process of bone remodeling is achieved by the finely balanced activity of osteoblasts in bone synthesis and osteoclasts in bone resorption. Both osteoblasts and osteoclasts express functional Epors, but the underlying mechanism of Epo-Epor signaling in bone homeostasis is incompletely understood. Two recent publications have provided new insights into the contribution of endogenous Epo to bone homeostasis. Suresh et al examined Epo-Epor signaling in osteoblasts in bone formation in mice and Deshet-Unger et al investigated osteoclastogenesis arising from transdifferentiation of B cells. Both groups also studied bone loss in mice caused by exogenous human recombinant EPO-stimulated erythropoiesis. They found that either deletion of Epor in osteoblasts or conditional knockdown of Epor in B cells attenuates EPO-driven bone loss. These findings have direct clinical implications because patients on long-term treatment for anemia may have an increased risk of bone fractures. Phase 3 trials of small molecule inhibitors of the PHD enzymes (hypoxia inducible factor-prolyl hydroxylase inhibitors [HIF-PHIs]), such as Roxadustat, have shown improved iron metabolism and increased circulating Epo levels in a titratable manner, avoiding the supraphysiologic increases that often accompany intravenous EPO therapy. The new evidence presented by Suresh and Deshet-Unger and their colleagues on the effects of EPO-stimulated erythropoiesis on bone homeostasis seems likely to stimulate discussion on the relative merits and safety of EPO and HIF-PHIs.

Modulation of the Production of Erythropoietin by Cytokines: In vitro Studies and Their Clinical Implications1

The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Anemia in Lymphoma: the Role of Cytokines

[The Role of Cytokines in Lymphoma with Anemia].

Erythropoietin Receptor Haploinsufficiency and in Vivo Interplay with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin 3

Physiology and pharmacology of erythropoietin

A Review of Key Regulators of Steady-State and Ineffective Erythropoiesis

Molecular Insights into the Oxygen-Sensing Pathway and Erythropoietin Expression Regulation in Erythropoiesis

Erythropoietin and Nonhematopoietic Effects

Study on Serum Erythropoietin Levels in Patients with Hematologic Malignancies

Erythropoietin in bone homeostasis—Implications for efficacious anemia therapy

Clinical Application of Erythropoietin

Erythropoietin directly stimulates osteoclast precursors and induces bone loss

Erythropoietin enhances Kupffer cell number and activity in the challenged liver

Normal and dysregulated crosstalk between iron metabolism and erythropoiesis

The polymorphonuclear leukocyte--a new target for erythropoietin

Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach

Synergistic Effect Of Cytokines Epo, Il-3 And Scf On The Proliferation, Differentiation And Apoptosis Of Erythroid Progenitor Cells

Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacological Perturbations

Erythropoietin Effect on Complement Activation in Chronic Kidney Disease

[Erythropoietin: indications and measurement]